Case Study: In Re Rigel Pharma Securities Litigation

Law360, New York (September 25, 2012, 2:21 PM EDT) -- On Sept. 6, 2012, the United States Court of Appeals for the Ninth Circuit issued a decision in In re Rigel Pharmaceutical Securities Litigation, No. 10-17619, which addressed the question of “whether statements concerning statistical results of a clinical trial may be considered false or misleading under Rule 10b-5 because the statistical methodology that produced those results was not the best or most acceptable methodology.” The court answered in the negative, holding that allegations that a pharmaceutical company used an imperfect methodology to present its clinical...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.